{"id":29807,"date":"2023-11-07T12:41:38","date_gmt":"2023-11-07T07:11:38","guid":{"rendered":"https:\/\/www.rankaza.com\/blog\/non-alcoholic-steatohepatitis-market-share-size-growth-opportunity-and-forecast-2023-2028\/"},"modified":"2023-11-07T12:41:38","modified_gmt":"2023-11-07T07:11:38","slug":"non-alcoholic-steatohepatitis-market-share-size-growth-opportunity-and-forecast-2023-2028","status":"publish","type":"post","link":"https:\/\/www.rankaza.com\/blog\/non-alcoholic-steatohepatitis-market-share-size-growth-opportunity-and-forecast-2023-2028\/","title":{"rendered":"Non-Alcoholic Steatohepatitis Market Share, Size, Growth, Opportunity and Forecast 2023-2028"},"content":{"rendered":"

The latest report by IMARC Group, titled \u201cNon-Alcoholic Steatohepatitis (NASH) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028\u201c.\u00a0<\/strong>offers a comprehensive analysis of the industry, which comprises insights on the global\u00a0non-alcoholic steatohepatitis market share<\/a>.\u00a0<\/strong>The global market size reached US$ 1.21 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.55 Billion by 2028, exhibiting a growth rate (CAGR) of 27.70% during 2023-2028.<\/p>\n

Non-alcoholic steatohepatitis (NASH) is a liver condition characterized by inflammation and the accumulation of fat deposits in the liver, absent of excessive alcohol consumption. It is a severe form of non-alcoholic fatty liver disease (NAFLD) and can progress to more critical liver diseases such as cirrhosis and liver cancer if left untreated. NASH is often asymptomatic in its early stages, making it difficult to diagnose without specific tests. It typically affects individuals with obesity, type 2 diabetes, or high cholesterol levels. Due to its chronic nature, the management of NASH generally involves lifestyle changes and may require pharmacological intervention. Given the implications on long-term liver health and the increasing prevalence of NASH, there is a growing necessity for effective treatments and diagnostic methods within the healthcare industry.<\/p>\n

Request Your Sample Report Now:\u00a0<\/strong>https:\/\/www.imarcgroup.com\/non-alcoholic-steatohepatitis-market\/requestsample<\/a><\/p>\n

Non-Alcoholic Steatohepatitis (NASH) Market Trends and Drivers:<\/strong><\/p>\n

The global non-alcoholic steatohepatitis (NASH) market is primarily driven by the rising incidence of obesity and type 2 diabetes worldwide, both of which are risk factors for developing NASH. As awareness around the condition grows, more healthcare facilities are focusing on early diagnosis and treatment, which in turn fuels the market for NASH-related pharmaceuticals and diagnostic tools. Additionally, ongoing research and development (R&D) in the sector aims to bring more targeted treatments to the market, potentially offering better patient outcomes. In line with this, the increasing adoption of sedentary lifestyles has contributed to the uptick in NASH cases, prompting greater emphasis on preventative healthcare measures, thus propelling market growth. Furthermore, advancements in liver biopsy techniques and imaging studies are providing a positive thrust to the diagnosis sector within the industry, thereby contributing to market growth.<\/p>\n

Report Segmentation:<\/strong><\/p>\n

The report has segmented the market into the following categories:<\/strong><\/p>\n

Drug Type Insights:<\/strong><\/p>\n